Unlocking the Potential of ALA

The benefits of alpha-lipoic acid are well documented. It helps control diabetic neuropathy as well as increase insulin sensitivity and glucose disposal. The one drawback, when taken in oral form, has been how quickly it is cleared out of the system. In fact, the plasma half-life is 26 minutes. Increasing the time in plasma (TIP) is the novel feature of Glucotize.

Glucotize: Maintaining Therapeutic Plasma Levels of ALA

Glucotize was invented to mimic the sustained therapeutic levels of ALA in plasma. A patented controlled-release (sustained-release) technology was applied. The result was achieving a 10-fold magnification in plasma time of ALA. Clinical trials were then run to test for safety and efficacy.

An IRB-approved human study on the effect of Glucotize on type II diabetics has now been completed. The results are published in Endocrine Practice Vol. 8, No. 1 January/February. Patients received 12 weeks of active treatment, 900 mg/day for 6 weeks and 1200 mg/day for 6 weeks. Subjects remained on existing anti-hyperglycemic medications. They were monitored on a regular basis for glucose and lipid control, liver enzymes, and other clinical markers. The results are as follows:

Safety Data

• No significant side effects
• No changes in liver enzyme or liver function
• No changes in kidney function
  

Efficacy Data

• Clinically-significant reduction on plasma fructosamine
• Reduction of glycated hemoglobin (HbA1c) in about 50% of the patients